Stifel Nicolaus downgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a buy rating to a hold rating in a research report report published on Friday, MarketBeat reports. The brokerage currently has $5.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $8.00.
Several other equities research analysts also recently issued reports on PETX. Zacks Investment Research raised Aratana Therapeutics from a hold rating to a buy rating and set a $7.75 price objective for the company in a research note on Saturday, November 10th. BidaskClub downgraded Aratana Therapeutics from a buy rating to a hold rating in a research note on Wednesday, October 17th. TheStreet raised Aratana Therapeutics from a d rating to a c- rating in a research note on Wednesday, November 21st. Finally, ValuEngine raised Aratana Therapeutics from a sell rating to a hold rating in a research note on Monday, October 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aratana Therapeutics presently has an average rating of Buy and an average price target of $7.50.
Shares of NASDAQ PETX traded down $1.58 during mid-day trading on Friday, hitting $4.37. 6,796,287 shares of the company traded hands, compared to its average volume of 1,329,649. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.16. The company has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. The company has a quick ratio of 2.70, a current ratio of 3.17 and a debt-to-equity ratio of 0.02.
In related news, insider Ernst Heinen sold 19,308 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the completion of the sale, the insider now directly owns 135,694 shares of the company’s stock, valued at approximately $943,073.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Peter Steven St sold 11,513 shares of the stock in a transaction dated Tuesday, October 30th. The stock was sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the sale, the insider now directly owns 562,720 shares of the company’s stock, valued at $3,297,539.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 77,607 shares of company stock valued at $476,116. Company insiders own 5.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Hollencrest Capital Management acquired a new position in Aratana Therapeutics in the 4th quarter worth about $153,000. Bank of Montreal Can increased its position in Aratana Therapeutics by 152.9% in the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 31,053 shares during the last quarter. Northern Trust Corp increased its position in Aratana Therapeutics by 7.2% in the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after purchasing an additional 32,773 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics in the 3rd quarter worth about $215,000. Finally, American Century Companies Inc. acquired a new position in Aratana Therapeutics in the 2nd quarter worth about $195,000. 67.92% of the stock is currently owned by institutional investors.
About Aratana Therapeutics
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.
Recommended Story: Analyst Ratings Trading
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.